Pancreatic Cancer Research

ResearcherWenzhou Medical UniversityNo recent work listed

Huijing Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5882-3531; OpenAlex author ID A5021707700. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: 2 papers

Papers 3

  1. ESE1/AGR2 axis antagonizes TGF-β-induced epithelial-mesenchymal transition in low-grade pancreatic cancer. Co-author DOI 10.1002/cam4.5397↗
  2. High level of ANO1 promotes pancreatic cancer growth in concert with oncogenic KRAS. Co-author DOI 10.1007/s11033-023-08293-9↗
  3. The WW domains dictate isoform-specific regulation of YAP1 stability and pancreatic cancer cell malignancy. Co-author DOI 10.7150/thno.42795↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Meiyu Quan · 2 shared papers, 2020–2023 · strength 0.25
  2. Jin‐San Zhang · 2 shared papers, 2020–2023 · strength 0.25
  3. Lei Zhang · 1 shared paper, 2023 · strength 0.22
  4. Meiyan Sun · 1 shared paper, 2023 · strength 0.22
  5. Jie Wang · 1 shared paper, 2023 · strength 0.16
  6. Zhenkun Lou · 1 shared paper, 2020 · strength 0.09
  7. Qiang Guo · 1 shared paper, 2020 · strength 0.09
  8. Wei Wang · 1 shared paper, 2020 · strength 0.09
  9. Daniel D. Billadeau · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.